|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
  Dermatologic TherapyVolume 20 Issue 4, Pages 277 - 287 Published Online: 25 Oct 2007 © 2010 Wiley Periodicals, Inc.
Abstract | References | Full Text: HTML, PDF (Size: 102K) | Related Articles | Citation Tracking  Off-label uses of rituximab in dermatology This paper is completely self-generated and has not received any outside funding. This paper only reflects the views of its authors. Dr Heffernan has been a paid investigator, lecturer and/or consultant for Abbott, Amgen, Biogen-IDEC, Centocor and Genentech. Contents of this manuscript were presented at the 64th Annual Meeting of the American Academy of Dermatology. Copyright © Blackwell Publishing, Inc., 2007 KEYWORDS biologics • rituximab ABSTRACTABSTRACT: Since its approval in 1997 by the FDA, rituximab has been approved for use in certain B-cell lymphomas and treatment-resistant rheumatoid arthritis. Over the past 10 years, many case reports have indicated rituximab's efficacy in a number of inflammatory conditions in dermatology. This article includes a review of the mechanism of action, dosing, and side effect profile, as well as a review of the current literature on off-label uses of the CD20 | 
|
